Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.59 |
| ▸ | HTR5A | P47898 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.48 |
| ▸ | HTR2B | P41595 | 12/20 | 0.46 |
| ▸ | HTR2C | P28335 | 10/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 7/20 | 0.46 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269776 | 0.92 | HRH2 (0.59) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL18352583 | 0.91 | HRH2 (0.52) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL12269874 | 0.91 | HSP90B1 (0.59) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL24220655 | 0.87 | HRH2 (0.77) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL14401404 | 0.87 | HRH2 (0.77) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL18353150 | 0.84 | HRH2 (0.51) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL17830426 | 0.83 | HRH2 (0.58) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL19415065 | 0.82 | HTR2B (0.55) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL12269794 | 0.82 | HTR2B (0.55) | HRH2HTR5AADORA1ADORA3HTR2B | |
| SCHEMBL16440573 | 0.82 | HRH2 (0.48) | HRH2HTR5AADORA1ADORA3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526739-B2 | Compositions and methods to treat cardiac diseases | UNIVERSITY OF CONNECTICUT (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160166591-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | GOOGLE LLC | 2016-06-16 | — | — | US | disclosed |
| US-9303053-B2 | Compositions and methods to treat cardiac diseases | UNIVERSITY OF CONNECTICUT (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150038463-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | UNIV CONNECTICUT (US) | 2015-02-05 | — | — | US | disclosed |
| US-8822434-B2 | Compositions and methods to treat cardiac diseases | THE UNIVERSITY OF CONNECTICUT (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110212924-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | UNIVERSITY OF CONNECTICUT | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212924-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | P2RY12, P2RX6, P2RY14 | HRH2 1177/4885HTR5A 688/4885ADORA1 29/4885 |
| US-20150038463-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | P2RY12, P2RX6, P2RY14 | HRH2 1177/4885HTR5A 688/4885ADORA1 29/4885 |
| US-20160166591-A1 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES | P2RY12, P2RX6, P2RY14 | HRH2 1177/4885HTR5A 688/4885ADORA1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.